Document:

Exhibit 10.12

 

Equity Transfer Agreement

 

Transferor: [   ]

 

Assignee: Beijing Lianghua Technology Co., Limited

 

If there is any discrepancy between Chinese
and English, the Chinese shall prevail

 

	1.	The transferor agrees to transfer the equity interest in Youjiayoubao (Beijing) Technology Co., Limited
in the amount of [   ] million (RMB) to the transferee.

 

	2.	The transferee agrees to receive the transferor’s equity interest in Youjiayoubao (Beijing) Technology
Co., Limited in the amount of [   ] million (RMB)

 

	3.	The transfer will be officially carried out on [DATE]. From the date of the transfer, the transferor will
no longer enjoy the rights or assume the obligations as a capital contributor in connection with the transferred capital contribution,
and the transferee will enjoy the rights and assume the obligations as a capital contributor of Youjiayoubao (Beijing) Technology Co.,
Limited in connection with the transferred capital contribution.

 

This agreement will take effect after being signed
(sealed) by both parties.

 

Transferor’s signature:

 

Assignee’s signature:

 

[DATE]Exhibit
10.13

 

Investment
Cooperation Agreement

 

No.:
[  ]

 

Party
A: U-BX Technology Ltd. 

Legal
representative: Chen Jian

Tel:
[  ]

Address:
Room 11A18, Building 2, Beijing INN, Building 5, Dongshuijing Hutong, Dongcheng District, Beijing

Email:
chenjian@u-bx.com

 

Party
B: [  ]

ID
number: [  ]

Tel:
[  ]

Address:
[  ]

E-mail:
[  ]

 

The
two parties have signed this agreement through friendly negotiation on matters related to the investment and cooperation between Party
B and Party A, based on the principles of equality, mutual benefit and integrity.

 

In
case of any ambiguity between Chinese and English, the Chinese version shall prevail

 

I.
Basic matters

 

1.
Party A is a company established in Cayman Islands applying to list its securities on Nasdaq.

 

2.
Party B intends to invest in Party A and obtain Party A's shares.

 

II.
Investment matters

 

1.
Party B contributed USD[  ], and the payment has been made directly to Party A's account on [ ], and Party A has confirmed
that the payment has been received.

 

2.
Based on Party B's capital contribution, it is determined that Party B's shareholding in Party A is [ ]%. Party A cause the ordinary
shares to be registered in Party B’s name after the capital contribution is in place.

 

III.
Party A's receiving account information

 

[  
]

 

IV.
Party A's rights and obligations

 

1.
After Party A receives the capital contribution from Party B, it can use it according to its own needs, and Party B shall not interfere.

 

2.
Party A shall cooperate with Party B to go through the procedures of equity registration and transfer.

 

3.
Party A warrants that the equity involved has the full right to dispose of it, and there is no pledge or guarantee.

 

4.
Party A accepts Party B’s entrustment to Party A, and its designees, to exercise all their rights (except the right to profit)
as a holder of the ordinary shares of Party A, including but not limited to voting rights, voting rights and disposal rights on behalf
of Party B.

 

5.
The expenses involved in the process of equity transfer shall be borne by Party A.

 

     

     

    

 

V.
Rights and Obligations of Party B

 

1.
Party B shall pay the capital contribution on time.

 

2.
Party B shall have the right as a shareholder of Party to receive dividends or other distributions, attend the shareholders' meeting
and exercise voting rights and other rights granted to shareholders by Party A's Articles of Association.

 

3.
Party B hereby entrusts Party A, and its designees, to exercise all their rights (except the right to profit) as a holder of the ordinary
shares of Party A, including but not limited to voting rights, voting rights, disposal rights, etc. Party B unconditionally agrees to
any decision made by Party A and does not raise any objection.

 

4.
Party B shall not carry out any behavior that may damage the interests of Party A and affect the listing of the company.

 

5.
If Party A needs Party B's cooperation in handling relevant procedures, Party B shall cooperate unconditionally.

 

VI.
Repurchase Terms

 

1.
After listing, if Party A's shares cannot be sold or there is a loss after the sale, Party B has the right to request Party A to repurchase
the shares unconditionally, and the repurchase price is the amount of Party B's capital contribution (interest free).

 

2.
If Party A fails to go public within 24 months after the agreement takes effect, Party B has the right to request Party A to repurchase
the equity unconditionally. Interest is calculated as simple interest of 4% per annum.

 

VII.
Validity period of the agreement

 

This
agreement is valid from the time when the funds are remitted to the account designated by Party A, until Party B holds no ordinary shares
of Party A.

 

VIII.
Confidentiality clause

 

Both
parties are obliged to keep confidential any business information of the other party that they come into contact with or learn during
the performance of this agreement, unless there is obvious evidence that such information is public information or prior written authorization
from the other party is obtained. Such confidentiality obligations shall survive the termination of this Agreement. If either party causes
losses to the other party due to breach of these obligations, Both parties shall compensate the other party for the corresponding losses.

 

IX.
Liability for breach of contract

 

1.
If any party to the agreement fails to perform its obligations in accordance with the provisions of this agreement, it shall bear the
responsibility for breach of contract to the relevant parties.

 

2.
The above provisions do not affect the loss (including but not limited to various losses, attorney fees for claiming rights, litigation
fees, travel expenses, filing fees, etc.), the right to claim damages.

 

X.
Dispute Resolution

 

1.
The signing and interpretation of this agreement and the settlement of disputes related to this agreement are all bound by the current
laws of the People's Republic of China.

 

2.
Any disputes arising out of or related to this agreement shall first be resolved through friendly negotiation between the two parties.
If the parties cannot resolve the dispute through negotiation, either party may file a lawsuit with the people's court in the place where
this agreement is signed.

 

    2

     

    

 

XI.
Modification, cancellation and termination of this agreement

 

1.
Matters not covered in this agreement have been agreed upon by both parties, and both parties may sign a supplementary agreement to confirm
it. If the signed supplementary agreement is inconsistent with this agreement, the signed supplementary agreement shall prevail.

 

2.
This agreement can be changed, cancelled or terminated after mutual agreement.

 

XII.
Effectiveness and others

 

1.
This agreement is made in two copies, each party holds one copy, which has the same legal effect.

 

2.
This agreement will take effect from the date of signature and seal of both parties.

 

	Party A (seal):	Party B (signature):
	 	 
	 	 	Date: [  ] 
	 	 	 	Contract signing place: [  ]

 

 

 3Exhibit 10.3

 

NOVATION

of Agreement on Co-Development and the Terms of Exclusive License

 

This Novation of Agreement on Co-Development and
the Terms of Exclusive License (the “Agreement”) is made on December 17, 2021 between:

 

		(1)	Xenetic Biosciences (UK) Limited (formerly before 5th September 2011 Lipoxen PLC), a
Company registered under the laws of England with Company number 03213174 located at: 5th Floor, 15 Whitehall, London SW1A
2DD, United Kingdom, represented by its Director James Parslow, acting on the basis of the Articles of Association of Xenetic Biosciences
(UK) Limited;

 

		(2)	Lipoxen Technologies Limited, a Company registered under the laws of England with Company registration
number 03401495 located at: 5th Floor, 15 Whitehall, London SW1A 2DD, United Kingdom, represented by its Director James Parslow,
acting on the basis of the Articles of Association of Lipoxen Technologies Limited;

 

(Xenetic Biosciences (UK) Limited and Lipoxen
Technologies Limited shall be jointly referred to as “Xenetic”);

 

		(3)	SynBio LLC, a limited liability company incorporated under the laws of the Russian Federation,
Main State Registration Number 1117746126321, located at: 3, Molodezhnaya street, floor 1, premise XVII, office 1, room 17, 119296, Moscow,
Russian Federation (“SynBio”), represented by Chief Executive Officer Maxim Sirosh, acting on the basis of the Articles
of Association of SynBio; and

 

		(4)	Public Joint Stock Company Pharmsynthez, a corporation registered in the Russian Federation with
registration number 7801075160, with registered address at: No134, liter 1, Kuzmolovsky urban-type settlement, Capitolovo station,
Vsevolozhsky district, Leningrad region, 188663, Russian Federation (“Pharmsynthez”), represented by Chief Executive
Officer Efim Prilezhaev, acting on the basis of the Articles of Association of Pharmsynthez.

 

(Xenetic, SynBio and Pharmsynthez shall be jointly
referred to as the “Parties” and each individually as a “Party”).

 

BACKGROUND:

 

		(A)	On 4 August 2011, Xenetic and SynBio entered into an Agreement on Co-Development and the Terms of Exclusive
Licence (the “Agreement on Co-Development”) pursuant to which Xenetic and SynBio have agreed to collaborate in the
development of: (a) certain products combining the PolyXen Technology and SynBio Molecules; and (b) Histone using the Oncohist Technology.

 

		(B)	The Parties have agreed, and Xenetic hereby consents, that SynBio's rights, obligations and liabilities
under the Agreement on Co-Development shall be assumed by Pharmsynthez on the terms set out in this Agreement.

 

Words and expressions defined in the Agreement
on Co-Development shall have the same meaning when used herein.

 

 

 

    	 	1	 

     

    

 

THE PARTIES AGREE as follows:

 

		1.	NOVATION / CHANGE OF CONTRACTUAL PARTY

 

		1.1	The transfer of rights and obligations set out in this Clause 1 and Clause 2 shall be deemed to have
taken effect as from 17 December 2021 (the “Effective Date”). For the avoidance of doubt it is agreed that the terms
of the Agreement on Co-Development shall remain the same.

 

		1.2	As from the Effective Date:

 

		1.2.1	SynBio transfers all of its rights and obligations under the Agreement on Co-Development to Pharmsynthez.
Pharmsynthez shall enjoy all the rights and benefits of SynBio under the Agreement on Co-Development, and all references to “SynBio”
in the Agreement on Co-Development shall be read and construed as references to Pharmsynthez. Consequently the Parties to this Agreement
confirm that the transfer is made in accordance with clause 21.1 of the Agreement on Co-Development.

 

		1.2.2	Pharmsynthez agrees to perform the obligations of the Agreement on Co-Development and be bound by the
terms of the Agreement on Co-Development in every way as if it were the original party to them in place of SynBio; and

 

		1.2.3	Xenetic agrees to perform the obligations of the Agreement on Co-Development and be bound by the terms
of the Agreement on Co-Development in every way as if Pharmsynthez were the original party to it in place of SynBio.

 

		1.3	Nothing in this Agreement is intended to or shall deem Pharmsynthez to be liable for any act or omission
of SynBio in relation to the Agreement on Co-Development occurring before the Effective Date.

 

		2.	RELEASE OF OBLIGATIONS AND LIABILITIES

 

		2.1	Xenetic and SynBio release each other from all future obligations to the other under the Agreement on
Co-Development arising after the Effective Date.

 

		2.2	Xenetic releases and discharges SynBio from all claims and demands arising under or in connection with
the Agreement on Co-Development, except that nothing in this Agreement shall affect or prejudice any claim or demand that either Xenetic
or SynBio may have against the other relating to matters arising before the Effective Date.

 

		3.	OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS

 

		3.1	All SynBio Arising IPR under the Agreement on Co-Development (including but not limited to any patent
applications which may previously have been filed in the name of SynBio) shall belong to, and vest in, Pharmsynthez.

 

		3.2	All Joint Arising IP which at any time have been or are created, developed and/or acquired by or on behalf
of Xenetic and SynBio shall belong to Xenetic and Pharmsynthez.

 

 

 

    	 	2	 

     

    

 

		3.3	SynBio hereby transfers an exclusive license granted to SynBio by Xenetic during the term of the Agreement
on Co-Development, subject to the provisions of the Agreement on Co-Development, to Pharmsynthez outside the Excluded Field in the SynBio
Market to research, develop, manufacture, have manufactured, use, sell, supply and otherwise exploit the Pharmsynthez PolyXen Products
using:

 

	 	3.3.1	the PolyXen Patents and the PolyXen Know How;
	 	 	 
	 	3.3.2	the Lipoxen (Xenetic) Arising IPR; and
	 	 	 
	 	3.3.3	any and all CMO Arising IPR which is owned by Xenetic or in relation to which Xenetic has a right to grant
a licence.

 

		3.4	SynBio transfers a non-exclusive licence granted to SynBio by Xenetic to Pharmsynthez to use the PSA Patents
and the PSA Know How in the SynBio Market for the term of the Agreement on Co-Development to manufacture PSA:

 

		3.4.1	for use in the development and exploitation of Products by Pharmsynthez; and/or

 

		3.4.2	for supply to Xenetic and/or licensee’s of the PolyXen Technology.

 

		3.5	For the avoidance of doubt, SynBio acknowledges and agrees that, as from the Effective Date, it shall
have no further rights to develop and commercially exploit SynBio Products in the SynBio Market.

 

		3.6	The provisions of this Clause 3 shall be binding as from the date that this Agreement is executed and
the Agreement on Co-Development shall be deemed to be amended accordingly.

 

		4.	FURTHER ASSURANCE

 

		4.1	Each Party agrees (at each Party's own cost) to do, or procure the doing of, all acts and things, and
execute, or procure the execution of, all documents, as may be required from time to time to give full effect to the terms of this Agreement
and to perfect another Party's title to any IPR which is assigned to it pursuant to this Agreement.

 

		5.	GENERAL

 

		5.1	This Agreement shall be governed, interpreted, applied and construed in accordance with the English law.
This provision does not affect the application of the mandatory rules of Russian law established under Article 1192 of the civil Code
of the Russian Federation to this Agreement which apply in any event.

 

		5.2	If any dispute, controversy or claim of whatever nature arises under, out of or in connection with this
Agreement, including any question regarding its existence, validity or termination (a “Dispute”), the Parties shall
use all reasonable endeavours to resolve the matter amicably. If one Party gives the others notice that a Dispute has arisen and the Parties
are unable to resolve the Dispute within thirty (30) days of service of the notice then the Dispute shall be referred to the respective
chief executive officers of the Parties who shall attempt to resolve the Dispute. No Party shall resort to arbitration against any other
Party under this Agreement until thirty (30) days after such referral.

 

 

 

    	 	3	 

     

    

 

		5.3	All Disputes which are unresolved pursuant to Clause 5.2 and which a Party wishes to have resolved shall
be referred upon the application of any Party to, and finally settled by, arbitration under the Rules of Arbitration of the London Court
of International Arbitration (“LCIA”) (the “Rules”) in force at the date of this Agreement, which
Rules are deemed to be incorporated by reference to this Clause. The number of arbitrators shall be three (3), appointed in accordance
with the Rules. The LCIA Court may appoint arbitrators from among the nationals of any country, whether or not a Party is a national of
that country. The seat of the arbitration shall be London. The language of this arbitration shall be English.

 

		5.4	The arbitrators shall have the power to grant any legal or equitable remedy or relief available under
law, including injunctive relief (whether interim and/or final) and specific performance and any measures ordered by the arbitrators may
be specifically enforced by any court of competent jurisdiction. Each Party retains the right to seek interim or provisional measures,
including injunctive relief and including pre-arbitral attachments or injunctions, from any court of competent jurisdiction and any such
request shall not be deemed incompatible with the agreement to arbitrate or a waiver of the right to arbitrate. For the avoidance of doubt,
this Clause is not intended to limit the powers of the court exercisable in support of arbitration proceedings pursuant to s.44 of the
Arbitration Act 1996.

 

		5.5	This Agreement is executed in the Russian and English languages in four counterparts, one counterpart
for each Party. In the event of a discrepancy between the Russian and English texts of this Agreement, the English language text shall
prevail.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	4	 

     

    

 

IN WITNESS WHEREOF this Agreement
has been duly executed the day and year first above written.

 

	
    SIGNED for and on behalf of Xenetic
    Biosciences (UK) Limited

     

     

     

    Signed by: _______________________________

     

    Name: James Parslow

    Title: Director /

	 
	
    SIGNED for and on behalf of Lipoxen
    Technologies Limited

     

     

     

     

    Signed by : _______________________________

     

    Name: James Parslow

    Title: Director

     

	
    SIGNED for and on behalf of SynBio LLC

     

     

     

    Signed by: _______________________________

     

    Name: Maxim Sirosh

    Title: CEO

	 
	
    SIGNED for and on behalf of PJSC Pharmsynthez
    

     

     

     

     

    Signed by: _______________________________

     

    Nam: Efim Prilezhaev

    Title: CEO

 

 

    	 	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]